Medical Marijuana for ALS in Ohio

Amyotrophic lateral sclerosis — commonly known as ALS or Lou Gehrig’s disease — is one of Ohio’s recognized qualifying conditions for medical marijuana. ALS is a rapidly progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord, gradually impairing the ability to move, speak, swallow, and breathe. There is no cure. The limited treatments available focus on slowing disease progression and managing symptoms — which is where medical marijuana has generated increasing interest from patients, caregivers, and researchers alike.

This page is written for Ohio ALS patients and their caregivers — because in many cases, caregivers play a central role in pursuing and managing medical marijuana on behalf of a patient whose physical capacity to do so has become limited.

Does ALS Qualify for Medical Marijuana in Ohio?

Yes. ALS is explicitly listed as a qualifying condition under Ohio Revised Code Section 3796.01. A physician holding a Certificate to Recommend (CTR) issued by the State Medical Board of Ohio evaluates whether the patient’s documented ALS diagnosis and symptom picture support a medical marijuana recommendation.

Ohio law does not restrict the ALS qualifier to a specific disease stage. Patients at any point in their ALS journey may qualify — from early diagnosis to advanced disease — depending on the symptom burden and the physician’s clinical assessment.

Why ALS Patients Consider Medical Marijuana

ALS produces a wide range of symptoms that are often inadequately managed by standard treatments. In reviewing the clinical literature and patient experience data, the symptoms most commonly associated with medical marijuana consideration in ALS include spasticity and muscle cramps, pain from muscle strain and immobility, appetite loss and weight maintenance, depression and mood disturbance, drooling and sialorrhea, and sleep disruption.

What makes ALS particularly relevant to medical marijuana consideration is the nature of the disease — terminal, progressive, with extremely limited pharmacological options beyond riluzole and edaravone for disease modification. For many ALS patients and their families, quality of life in the time they have becomes the primary treatment goal — and that framing shapes how medical marijuana fits into the overall picture.

What Does the Research Show About Cannabinoids and ALS?

The Preclinical Promise — and Its Limits

Preclinical research has generated genuine interest in cannabinoids for ALS. A review published through PubMed found that experimental studies into the biology of the endocannabinoid system revealed that cannabinoids have efficacy not only in symptom relief but also as neuroprotective agents which may slow disease progression and delay onset of symptoms in ALS animal models. Preclinical data using the SOD1 G93A mouse model — the standard ALS research model — showed cannabis extracts prolonged neuronal cell survival and delayed disease progression in that model.

A comprehensive review published through PubMed found that cannabinoids including THC, CBD, CBG, and cannabis extracts appear to have activity in ALS pathogenic pathways — with preclinical data indicating powerful antioxidative, anti-inflammatory, and neuroprotective effects.

What Is Critical to State Clearly

Preclinical results in animal models have not yet translated into confirmed disease-modifying effects in human clinical trials. As the same review explicitly notes, research in humans remains limited and there remains a need for further well-designed clinical trials to validate the use of cannabinoids as disease-modifying therapy for ALS. Medical marijuana should not be positioned as a disease-modifying treatment for ALS in humans based on current evidence.

What Patient-Reported Research Shows for Symptom Management

The most widely cited human study in ALS cannabis research was a patient survey published through PubMed in which ALS patients using cannabis reported moderate effectiveness for appetite loss, depression, pain, spasticity, and drooling — with the longest reported relief for depression. A randomized placebo-controlled Phase 2 trial published in Lancet Neurology examining nabiximols — a cannabis-based medicine containing THC and CBD — for spasticity in motor neuron disease patients found significant improvement in spasticity scores in the active treatment group.

A systematic review published through PMC reviewing 304 studies on cannabis and ALS pain found high patient satisfaction with cannabis use for spasticity and related pain — and concluded that several studies suggest ALS is associated with changes in the endocannabinoid system with cannabis showing potential to act on pain, spasticity, cramps, sialorrhea, and depression.

Research from an Italian patient cohort published through PubMed found that ALS patients using cannabis or CBD reported benefits for both motor symptoms — including rigidity, cramps, and fasciculations — and non-motor symptoms including sleep quality, pain, emotional state, quality of life, and depression, with only minor adverse reactions reported.

What Cannabis Was Reported as Less Effective For

The patient survey is also notable for what ALS patients reported cannabis was not effective for — specifically difficulties with speech and swallowing, and sexual dysfunction. Setting honest expectations in these areas matters for patients considering medical marijuana.

Special Considerations for ALS Patients and Caregivers

Delivery Method Matters More in ALS Than in Most Conditions

As ALS progresses, swallowing difficulties — dysphagia — become common, and eventually respiratory function declines. This significantly affects which delivery methods are practical:

Oral products including tinctures and oils placed under the tongue are generally the most practical option for patients with swallowing difficulties. Vaporization may be appropriate at earlier disease stages but becomes less suitable as respiratory function declines. Topical products may be relevant for localized pain or spasticity without systemic effects. Edibles requiring swallowing become progressively less practical as dysphagia advances.

Discussing delivery method appropriateness with both the evaluating physician and the patient’s ALS care team is particularly important.

Caregiver Involvement

As with Alzheimer’s disease, ALS patients at later stages of disease may need caregiver assistance in pursuing and managing medical marijuana. Ohio’s program includes caregiver registration — allowing a designated caregiver to assist with purchasing and managing the patient’s medical marijuana. The evaluating physician can discuss caregiver registration during the evaluation call.

What Documentation Is Needed for an Ohio ALS Evaluation?

The documentation picture for ALS is typically clear given the nature of the diagnosis:

Neurologist records confirming the ALS diagnosis are the most important document. Current ALS medications — including riluzole, edaravone, or other medications being used for symptom management — must be disclosed for the OARRS check and for assessing potential drug interactions. Symptom documentation noting specific symptoms being targeted — spasticity, pain, appetite, mood — helps the physician understand what the patient is seeking to manage. Caregiver identification if the patient requires assistance managing the evaluation process.

Scheduling an Ohio Medical Marijuana Evaluation for ALS

The telemedicine format of Ohio’s evaluation process is particularly practical for ALS patients whose mobility or speech may be affected. A caregiver or family member may participate in the call alongside the patient. The evaluation involves a brief video consultation reviewing the diagnosis, symptom picture, and current medications — followed by registry submission if approved and digital card activation via email, valid at any licensed Ohio dispensary statewide.

If the physician determines the patient does not qualify there is no charge. If you are an Ohio ALS patient or caregiver exploring medical marijuana as a quality-of-life option, you can schedule an evaluation here.

Frequently Asked Questions

Sources

• Ohio Revised Code Section 3796.01 — Qualifying Medical Conditions — Ohio Laws
• State Medical Board of Ohio — Medical Marijuana Program — med.ohio.gov
• Ohio Patient & Caregiver Registry — Ohio Division of Cannabis Control
• Survey of Cannabis Use in Patients With ALS — PubMed
• Endocannabinoids in Multiple Sclerosis and ALS — PubMed
• ALS, the Endocannabinoid System, and Exogenous Cannabinoids — PubMed
• Cannabis and ALS Pain and Spasticity: A Systematic Review — PMC / NIH